<DOC>
	<DOCNO>NCT02286700</DOCNO>
	<brief_summary>The purpose study compare effect amino acid moisturize cream desonide cream reduce skin symptom associate AD/eczema subject mild moderate atopic dermatitis/eczema .</brief_summary>
	<brief_title>Skin Effects Topical Amino Acid Moisturizing Cream Desonide Atopic Dermatitis</brief_title>
	<detailed_description>This double-blind , randomize study compare effect amino acid moisturize cream desonide cream reduce skin symptom associate AD/eczema subject mild moderate atopic dermatitis/eczema . Atopic dermatitis ( AD ) , also know Eczema , chronic inflammatory skin disease commonly affect infant child prevalence 10-20 % child compare 1-3 % adult . Patients AD dry , irritated skin often experience severe pruritus . Treatment AD involve avoidance trigger infectious agent , cutaneous hydration , control pruritus , anti-inflammatory agent . Topical calcineurin inhibitor steroid commonly use prescription anti-inflammatory treatment . Unfortunately , potential side effect long-term topical glucocorticoid use include skin atrophy , development stria , perioral dermatitis , acne , even hypothalamic-pituitary-adrenal axis suppression . However , many moisturizers available without prescription soothe skin reduce symptom associate AD/eczema via increase hydration , improve barrier function anti-irritancy effect . The study cream compare desonide cosmetic moisturize formulation contain cosmetic amino acid dipeptide ( e.g. , contain 2 amino acid ) . This study conduct understand benefit amino acid dipeptide moisturize cream versus dermatologist-prescribed desonide cream reduce symptom associate AD/eczema order evaluate potential use eczema care market . For study , approximately 60 male female , 18 year age old , general good health , diagnose mild moderate AD/eczema , recruit , screen , fully consent , goal enrol 42 evaluable subject . The 42 Subjects ( 21 subject per group ) randomly equally assign either one 2 treatment group amino acid moisturize cream desonide cream . Neither study subject study staff aware treatment assign . The subject ask participate approximately 5 week , 5 study visit : Screening/Baseline , Weeks 1-3 ( Treatment Period ) , Regression week 4 &amp; 5 . Each subject receive one , 15 gram , blind study cream treatment visit apply twice daily home 3 week ; 2-week regression phase study cream follow treatment phase . A predetermined target lesion assess time point via establish clinical grading scale include : Target lesion Atopic Dermatitis Severity Index ( TADSI ) , Eczema Area Severity Index ( EASI ) , Static IGA target lesion , Total IGA ( PGA ) Body Surface Area involvement . All grade complete principal sub-investigators . Photographs also take time point ass change treatment regression phase . Other establish scale utilized collect patient perception skin effect : Patient-Oriented Eczema Measure ( POEM ) , subject ' assessment pruritus ( VAS ) ; self-assessment questionnaire utilized collect information perceive benefit product aesthetic . This study IRB approve schedule begin November 2014 Massachusetts General Hospital , specifically Clinical Unit Research Trials Skin ( CURTIS ) principal investigator , Alexandra B. Kimball , MD . The study sponsor NeoStrata Company , Inc , Princeton , NJ .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Desonide</mesh_term>
	<criteria>1 . Male female subject general good health 18 year age old 2 . Diagnosis atopic dermatitis make base clinical criterion . Each patient must least one eczematous target lesion area range 10500 cm2 mild moderate severity grade least 6 TADSI scale , plus presence itch 3 . Body surface area affect AD lesion : â‰¤ 5 % start treatment 1 . Pregnancy breastfeed 2 . Any condition therapy investigator 's opinion may pose risk subject could interfere evaluation study 3 . Widespread AD require systemic therapy 4 . Diagnosis allergic contact dermatitis 5 . Known hypersensitivity constituent excipients investigational product 6 . Diagnosed immunocompromised status 7 . Use systemic AD therapy , e.g . systemic corticosteroid , cyclosporine A , azathioprine , mycophenolate mofetil , phototherapy past 1 month . 8 . Use phototherapy past 2 week 9 . Use topical AD therapy corticosteroid topical immunomodulators past 2 week 10 . Use local antiitch medical device treatment , e.g . benadryl , atopiclair , epiceram past 2 week 11 . Use topical moisturizers less 24 hour advance baseline visit eczema lesion 12 . Participation another clinical research study investigational drug within 4 week randomization study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>dermatitis , eczema , itch , moisturizer , amino acid</keyword>
</DOC>